Daphne Karydas insider trades: Mineralys Therapeutics (MLYS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Daphne reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | MLYS | ↓ Sell | 3,000 | $28.58 | $86K | Direct | Sep 17, 2026 (2d) |
| Jun 17, 2026 | MLYS | ↓ Sell | 3,000 | $25.00 | $75K | Direct | Jun 17, 2026 (0d) |
| Mar 31, 2026 | MLYS | ↓ Sell | 3,000 | $25.00 | $75K | Direct | Apr 2, 2026 (2d) |
| Nov 13, 2025 | MLYS | ↓ Sell | 15,000 | $45.99 | $690K | Direct | Nov 13, 2025 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other MLYS insiders
Open-market trades in the last 12 months
About Daphne Karydas's insider trades
Daphne Karydas is a director at Mineralys Therapeutics (MLYS). Since Nov 13, 2025, Daphne has reported no open-market purchases and 4 sales worth $926K on SEC Form 4. In the last 12 months: 4 sales ($926K).
Their filings also include grants and awards (12 filings), option exercises (4 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MLYS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.